In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi's Handsome Buyout Price Validates Plexxikon's Business Model

Executive Summary

In an era in which biotechs struggle to get financing and Big Pharma is hungry for new drugs but typically favors deals that delay rewards, Plexxikon Inc. appears to have been dealt a top R&D hand and played its cards exceedingly well. Its strategy has culminated in one of the priciest private buyouts in recent history, its $805 million up-front acquisition by Japan’s Daiichi Sankyo Co. Ltd.
Advertisement

Related Content

IND Over POC: The New Sweet Spot For Biopharma Dealmaking
Bridging The Gap Between Sell- And Buy- Sides In Biopharma Business Development
Bridging The Gap Between Sell- And Buy- Sides In Biopharma Business Development
IND Over POC: The New Sweet Spot For Biopharma Dealmaking
ASCO 2011: The Rapidly Changing Melanoma Market
What New Cancer Pathway Programs Mean For The Drug Industry
Plexxikon CEO: Expect Business As Usual, After Whopping $805 Million Daiichi Sankyo Buyout
Biotech Backers Are Learning to Live with Exit-by-Earn-out
The $100 Million IND
The $100 Million IND

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003606

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel